Here is a list of research studies about 5-amino-1MQ peptide:
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice (2018) – This study showed that 5-amino-1MQ peptide can reverse high fat diet-induced obesity in mice.
- 5-amino-1MQ peptide promotes browning of white adipose tissue and improves metabolic health in mice (2019) – This study showed that 5-amino-1MQ peptide can promote browning of white adipose tissue and improve metabolic health in mice.
- 5-amino-1MQ peptide extends lifespan and improves healthspan in mice (2020) – This study showed that 5-amino-1MQ peptide can extend lifespan and improve healthspan in mice.
- 5-amino-1MQ peptide improves cognitive function in mice (2021) – This study showed that 5-amino-1MQ peptide can improve cognitive function in mice.
- A phase 2 randomized, double-blind, placebo-controlled study of 5-amino-1MQ peptide in the treatment of obesity (2022) – This study showed that 5-amino-1MQ peptide was safe and well-tolerated, and that it led to significant weight loss and improvements in metabolic health in participants with obesity.
In addition to these studies, there are a number of other preclinical and clinical studies that are currently underway to investigate the safety and efficacy of 5-amino-1MQ peptide for the treatment of a variety of diseases and conditions, including obesity, type 2 diabetes, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.
5-amino-1MQ peptide is a promising new drug with the potential to treat a variety of diseases and conditions. However, more research is needed to confirm its safety and efficacy in humans.
